Suppr超能文献

[接受维生素K拮抗剂治疗患者的桥接抗凝:现状]

[Bridging anticoagulation in patients receiving vitamin K antagonists : Current status].

作者信息

Schellong S M, Riess H, Spannagl M, Omran H, Schwarzbach M, Langer F, Gogarten W, Bramlage P, Bauersachs R M

机构信息

Medizinische Klinik 2, Krankenhaus Dresden-Friedrichstadt, Friedrichstr. 41, 01067, Dresden, Deutschland.

Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.

出版信息

Anaesthesist. 2018 Aug;67(8):599-606. doi: 10.1007/s00101-018-0463-0.

Abstract

Approximately 30% of patients receiving oral anticoagulation using vitamin K antagonists (VKA) require surgery within 2 years. In this context, a clinical decision on the need and the mode of a peri-interventional bridging with heparin is needed. While a few years ago, bridging was almost considered a standard of care, recent study results triggered a discussion on which patients will need bridging at all. Revisiting the currently available recommendations and study results the conclusion can be drawn that the indications for bridging with heparin must nowadays be taken more narrowly and considering the individual patient risk of bleeding and thromboembolism. Bridging with heparin is only needed in patients with a very high risk of thromboembolism. This overview aims to give guidance for a risk-adapted peri-interventional approach to management of patients with a need for long-term anticoagulation using VKA.

摘要

接受维生素K拮抗剂(VKA)口服抗凝治疗的患者中,约30%在2年内需要进行手术。在此背景下,需要就围介入期使用肝素进行桥接治疗的必要性和方式做出临床决策。几年前,桥接治疗几乎被视为一种标准治疗方法,但最近的研究结果引发了关于哪些患者根本需要桥接治疗的讨论。回顾当前可用的建议和研究结果,可以得出结论,如今肝素桥接治疗的适应症必须更加严格,要考虑患者个体的出血和血栓栓塞风险。仅在血栓栓塞风险非常高的患者中需要进行肝素桥接治疗。本综述旨在为需要长期使用VKA抗凝的患者提供一种基于风险调整的围介入期管理方法的指导。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验